Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2016 3
2019 5
2020 7
2021 6
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganič I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. Vermeire S, et al. Among authors: kempinski r. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1024-1035. doi: 10.1016/S2468-1253(22)00233-3. Epub 2022 Sep 6. Lancet Gastroenterol Hepatol. 2022. PMID: 36075249 Clinical Trial.
Inflammatory bowel disease induced by bimekizumab.
Wietrzykowska-Grishanovich D, Pleskacz M, Kempiński R. Wietrzykowska-Grishanovich D, et al. Among authors: kempinski r. Prz Gastroenterol. 2022;17(2):175-176. doi: 10.5114/pg.2022.116374. Epub 2022 May 19. Prz Gastroenterol. 2022. PMID: 35664026 Free PMC article. No abstract available.
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Feagan BG, et al. Among authors: kempinski r. Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. Lancet. 2021. PMID: 34090625 Clinical Trial.
Standard versus Endocuff versus cap-assisted colonoscopy for adenoma detection: A randomised controlled clinical trial.
Floer M, Tschaikowski L, Schepke M, Kempinski R, Neubauer K, Poniewierka E, Kunsch S, Ameis D, Heinzow HS, Auer A, Schmidt HH, Ellenrieder V, Meister T. Floer M, et al. Among authors: kempinski r. United European Gastroenterol J. 2021 May;9(4):443-450. doi: 10.1177/2050640620982952. Epub 2021 Feb 16. United European Gastroenterol J. 2021. PMID: 33349200 Free PMC article. Clinical Trial.
L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs.
Krzystek-Korpacka M, Szczęśniak-Sięga B, Szczuka I, Fortuna P, Zawadzki M, Kubiak A, Mierzchała-Pasierb M, Fleszar MG, Lewandowski Ł, Serek P, Jamrozik N, Neubauer K, Wiśniewski J, Kempiński R, Witkiewicz W, Bednarz-Misa I. Krzystek-Korpacka M, et al. Among authors: kempinski r. Cancers (Basel). 2020 Sep 11;12(9):2594. doi: 10.3390/cancers12092594. Cancers (Basel). 2020. PMID: 32932854 Free PMC article.
26 results